Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors
- PMID: 10802620
- DOI: 10.1038/75390
Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors
Abstract
A major shortcoming to the use of adeno-associated virus (rAAV) vectors is their limited packaging size. To overcome this hurdle, we split an expression cassette and cloned it into two separate vectors. The vectors contained either a nuclear localizing Escherichia coli lacZ transgene (nlslacZ) with a splice acceptor, or the human elongation factor 1alpha ( EF1alpha) gene enhancer/promoter(s) (EF1alphaEP) with a splice donor. We co-injected a promoter-less nlslacZ vector with a vector containing either a single EF1alphaEP or a double copy of the EF1alphaEP in a head-to-head orientation, into the portal vein of mice. Gene expression, measured by both transduction efficiency and quantitation of the recombinant protein, was as much as 60-70% of that obtained from mice that received a single vector containing a complete EFalphaEP/nlslacZ expression cassette. This two-vector approach may allow development of gene therapy strategies that will carry exogenous DNA sequences with large therapeutic cDNAs and/or regulatory elements.
Comment in
-
Expanding the AAV package.Nat Biotechnol. 2000 May;18(5):497-8. doi: 10.1038/75352. Nat Biotechnol. 2000. PMID: 10802614 No abstract available.
Similar articles
-
Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors.Gene Ther. 2001 Sep;8(17):1299-306. doi: 10.1038/sj.gt.3301422. Gene Ther. 2001. PMID: 11571566
-
Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo.Gene Ther. 2008 Sep;15(18):1287-93. doi: 10.1038/gt.2008.89. Epub 2008 May 22. Gene Ther. 2008. PMID: 18496572
-
Enhanced transgene expression in the mouse skeletal muscle infected by the adeno-associated viral vector with the human elongation factor 1alpha promoter and a human chromatin insulator.J Gene Med. 2009 Jul;11(7):598-604. doi: 10.1002/jgm.1337. J Gene Med. 2009. PMID: 19399759
-
Size does matter: overcoming the adeno-associated virus packaging limit.Respir Res. 2000;1(1):16-8. doi: 10.1186/rr6. Epub 2000 Jul 5. Respir Res. 2000. PMID: 11667959 Free PMC article. Review.
-
[Expression of proteins in recombinant mammalian cells].Tanpakushitsu Kakusan Koso. 1992 Feb;37(3 Suppl):269-83. Tanpakushitsu Kakusan Koso. 1992. PMID: 1549706 Review. Japanese. No abstract available.
Cited by
-
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.Cell. 2020 Apr 2;181(1):136-150. doi: 10.1016/j.cell.2020.03.023. Cell. 2020. PMID: 32243786 Free PMC article. Review.
-
Regulatable gene expression systems for gene therapy applications: progress and future challenges.Mol Ther. 2005 Aug;12(2):189-211. doi: 10.1016/j.ymthe.2005.03.022. Mol Ther. 2005. PMID: 15946903 Free PMC article. Review.
-
A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction.Mol Ther. 2011 Jun;19(6):1079-89. doi: 10.1038/mt.2011.3. Epub 2011 Mar 1. Mol Ther. 2011. PMID: 21364543 Free PMC article.
-
Pseudotyped AAV vector-mediated gene transfer in a human fetal trachea xenograft model: implications for in utero gene therapy for cystic fibrosis.PLoS One. 2012;7(8):e43633. doi: 10.1371/journal.pone.0043633. Epub 2012 Aug 24. PLoS One. 2012. PMID: 22937069 Free PMC article.
-
Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells.Hum Gene Ther. 2008 Dec;19(12):1407-14. doi: 10.1089/hum.2008.117. Hum Gene Ther. 2008. PMID: 18778196 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources